NR4A1 and breast carcinoma: However, in the recently completed BOLERO-3 randomized phase-III study of Trastuzumab-resistant advanced breast cancer, the addition of the mTOR-inhibitor Everolimus to Trastuzumab and Vinorelbine treatment showed some clinical benefit only in hormone receptor negative (HR−) patients55.